These observations indicate an overactive mTOR and dysfunctional AMPK pathway in AMD PRE cells and suggest that mTORC1 rather than mTORC2 is responsible for mTOR dysregulation in AMD RPE, thus, may be targeted to develop therapies for AMD. This evidence concerns the gene MTOR and age-related macular degeneration.